Organ-On-A-Chip: Development and Clinical Prospects Toward Toxicity Assessment with an Emphasis on Bone Marrow

Drug Safety

Volumn 38, Issue 5, 2015, Pages 409-418

  Kim, Jeehye ^a,b,c   Lee, Hanna ^a,b,c   Selimović, Šeila ^a,b,c   Gauvin, Robert ^a,b,c   Bae, Hojae ^a,b,c  

^a Konkuk University   (South Korea)

^b AAAS   (United States)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

XENOBIOTIC AGENT;

ADVERSE DRUG REACTION; ANIMAL; BONE MARROW; DEVICES; DRUG EFFECTS; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOLOGY; LAB ON A CHIP; PROCEDURES; TISSUE ENGINEERING; TISSUE MICROARRAY; TOXICITY TESTING;

ANIMALS; BONE MARROW; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LAB-ON-A-CHIP DEVICES; TISSUE ARRAY ANALYSIS; TISSUE ENGINEERING; TOXICITY TESTS; XENOBIOTICS;

EID: 84937764527     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0284-x     Document Type: Article

References (98)

1. Nelson CM, Bissell MJ. Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. Semin Cancer Biol. 2005;15(5):342–52. doi:10.1016/j.semcancer.2005.05.001.
2. Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell. 2007;130(4):601–10.
3. Griffith LG, Swartz MA. Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol. 2006;7(3):211–24.
4. Huh D, Hamilton GA, Ingber DE. From 3D cell culture to organs-on-chips. Trends Cell Biol. 2011;21(12):745–54.
5. Neuži P, Giselbrecht S, Länge K, Huang TJ, Manz A. Revisiting lab-on-a-chip technology for drug discovery. Nat Rev Drug Discov. 2012;11(8):620–32.
6. Elliott NT, Yuan F. A review of three-dimensional in vitro tissue models for drug discovery and transport studies. J Pharm Sci. 2011;100(1):59–74.
7. United Nations, Department of Economic and Social Affairs. Consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by governments: chemicals. New York: United Nations; 2002.
8. Rovida C, Hartung T. Re-evaluation of animal numbers and costs for in vivo tests to accomplish REACH legislation requirements for chemicals—a report by the transatlantic think tank for toxicology (t (4)). Altex. 2009;26(3):187–208.
9. Marx U, Walles H, Hoffmann S, Lindner G, Horland R, Sonntag F, et al. ‘Human-on-a-chip’ developments: a translational cutting-edge alternative to systemic safety assessment and efficiency evaluation of substances in laboratory animals and man? Altern Lab Anim. 2012;40(5):235.
10. Tatosian DA, Shuler ML. A novel system for evaluation of drug mixtures for potential efficacy in treating multidrug resistant cancers. Biotechnol Bioeng. 2009;103(1):187–98.
11. Zeevi-Levin N, Itskovitz-Eldor J, Binah O. Cardiomyocytes derived from human pluripotent stem cells for drug screening. Pharmacol Ther. 2012;134(2):180–8.
12. Roep BO, Buckner J, Sawcer S, Toes R, Zipp F. The problems and promises of research into human immunology and autoimmune disease. Nat Med. 2012;18(1):48–53.
13. Novik E, Maguire TJ, Chao P, Cheng K, Yarmush ML. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem Pharmacol. 2010;79(7):1036–44.
14. Chao P, Maguire T, Novik E, Cheng K-C, Yarmush M. Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem Pharmacol. 2009;78(6):625–32.
15. Ferrell N, Ricci KB, Groszek J, Marmerstein JT, Fissell WH. Albumin handling by renal tubular epithelial cells in a microfluidic bioreactor. Biotechnol Bioeng. 2012;109(3):797–803.
16. Hinderer S, Schesny M, Bayrak A, Ibold B, Hampel M, Walles T, et al. Engineering of fibrillar decorin matrices for a tissue-engineered trachea. Biomaterials. 2012;33(21):5259–66.
17. Huh D, Leslie DC, Matthews BD, Fraser JP, Jurek S, Hamilton GA, et al. A human disease model of drug toxicity–induced pulmonary edema in a lung-on-a-chip microdevice. Sci Transl Med. 2012;4(159ra159):47.
18. Brauchle E, Johannsen H, Nolan S, Thude S, Schenke-Layland K. Design and analysis of a squamous cell carcinoma in vitro model system. Biomaterials. 2013;34(30):7401–7.
19. Ataç B, Wagner I, Horland R, Lauster R, Marx U, Tonevitsky AG, et al. Skin and hair on-a-chip: in vitro skin models versus ex vivo tissue maintenance with dynamic perfusion. Lab Chip. 2013;13(18):3555–61.
20. Wagner I, Materne E-M, Brincker S, Süßbier U, Frädrich C, Busek M, et al. A dynamic multi-organ-chip for long-term cultivation and substance testing proven by 3D human liver and skin tissue co-culture. Lab Chip. 2013;13(18):3538–47.
21. Pusch J, Votteler M, Göhler S, Engl J, Hampel M, Walles H, et al. The physiological performance of a three-dimensional model that mimics the microenvironment of the small intestine. Biomaterials. 2011;32(30):7469–78.
22. Esch MB, Sung JH, Yang J, Yu C, Yu J, March JC, et al. On chip porous polymer membranes for integration of gastrointestinal tract epithelium with microfluidic ‘body-on-a-chip’ devices. Biomed Microdevices. 2012;14(5):895–906.
23. Giese C, Marx U. Human immunity in vitro—solving immunogenicity and more. Adv Drug Deliv Rev. 2014;69:103–22.
24. Esch MB, Mahler GJ, Stokol T, Shuler ML. Body-on-a-chip simulation with gastrointestinal tract and liver tissues suggests that ingested nanoparticles have the potential to cause liver injury. Lab Chip. 2014;14(16):3081–92.
25. Moraes C, Mehta G, Lesher-Perez SC, Takayama S. Organs-on-a-chip: a focus on compartmentalized microdevices. Ann Biomed Eng. 2012;40(6):1211–27.
26. Ghaemmaghami AM, Hancock MJ, Harrington H, Kaji H, Khademhosseini A. Biomimetic tissues on a chip for drug discovery. Drug Discov Today. 2012;17(3):173–81.
27. Tsui JH, Lee W, Pun SH, Kim J, Kim D-H. Microfluidics-assisted in vitro drug screening and carrier production. Adv Drug Deliv Rev. 2013;65(11):1575–88.
28. Tay CY, Irvine SA, Boey FY, Tan LP, Venkatraman S. Micro-/nano-engineered cellular responses for soft tissue engineering and biomedical applications. Small. 2011;7(10):1361–78.
29. Kamei K-I, Hirai Y, Tabata O. Body on a chip: re-creation of a living system in vitro. Nanotechnol Mag IEEE. 2013;7(3):6–14.
30. Qi H, Huang G, Han YL, Lin W, Li X, Wang S et al. In vitro spatially organizing the differentiation in individual multicellular stem cell aggregates. Crit Rev Biotechnol. 2014:1–12.
31. van de Stolpe A, den Toonder J. Workshop meeting report organs-on-chips: human disease models. Lab Chip. 2013;13(18):3449–70. doi:10.1039/C3LC50248A.
32. Khetani SR, Bhatia SN. Microscale culture of human liver cells for drug development. Nat Biotechnol. 2007;26(1):120–6.
33. Grosberg A, Alford PW, McCain ML, Parker KK. Ensembles of engineered cardiac tissues for physiological and pharmacological study: heart on a chip. Lab Chip. 2011;11(24):4165–73. doi:10.1039/C1LC20557A.
34. HwanáSung J. Microscale 3-D hydrogel scaffold for biomimetic gastrointestinal (GI) tract model. Lab Chip. 2011;11(3):389–92.
35. Nakao Y, Kimura H, Sakai Y, Fujii T. Bile canaliculi formation by aligning rat primary hepatocytes in a microfluidic device. Biomicrofluidics. 2011;5(2):022212.
36. Bae H, Puranik AS, Gauvin R, Edalat F, Carrillo-Conde B, Peppas NA, et al. Building vascular networks. Sci Transl Med. 2012;4(160):160ps23.
37. Sudo R, Chung S, Zervantonakis IK, Vickerman V, Toshimitsu Y, Griffith LG, et al. Transport-mediated angiogenesis in 3D epithelial coculture. FASEB J. 2009;23(7):2155–64.
38. Esch MB, Post DJ, Shuler ML, Stokol T. Characterization of in vitro endothelial linings grown within microfluidic channels. Tissue Eng Part A. 2011;17(23–24):2965–71.
39. Young EW, Beebe DJ. Fundamentals of microfluidic cell culture in controlled microenvironments. Chem Soc Rev. 2010;39(3):1036–48.
40. Park S-H, Sim WY, Min B-H, Yang SS, Khademhosseini A, Kaplan DL. Chip-based comparison of the osteogenesis of human bone marrow-and adipose tissue-derived mesenchymal stem cells under mechanical stimulation. PLoS One. 2012;7(9):e46689.
41. Derendorf H, Meibohm B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res. 1999;16(2):176–85.
42. Sung JH, Shuler ML. A micro cell culture analog (µCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. Lab Chip. 2009;9(10):1385–94.
43. Sung JH, Kam C, Shuler ML. A microfluidic device for a pharmacokinetic–pharmacodynamic (PK–PD) model on a chip. Lab Chip. 2010;10(4):446–55.
44. Torisawa Y-s, Spina CS, Mammoto T, Mammoto A, Weaver JC, Tat T, et al. Bone marrow–on–a–chip replicates hematopoietic niche physiology in vitro. Nat Methods. 2014;11(6):663–9. doi:10.1038/nmeth.2938.
45. Walasek MA, van Os R, de Haan G. Hematopoietic stem cell expansion: challenges and opportunities. Ann N Y Acad Sci. 2012;1266(1):138–50.
46. Lévesque J-P, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Investig. 2003;111(2):187–96. doi:10.1172/JCI15994.
47. Levesque J-P, Liu F, Simmons PJ, Betsuyaku T, Senior RM, Pham C, et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood. 2004;104(1):65–72. doi:10.1182/blood-2003-05-1589.
48. Katayama Y, Battista M, Kao W-M, Hidalgo A, Peired AJ, Thomas SA, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell. 2006;124(2):407–21. doi:10.1016/j.cell.2005.10.041.
49. Lévesque J-P, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood. 2001;98(5):1289–97. doi:10.1182/blood.V98.5.1289.
50. Nilsson SK, Johnston HM, Whitty GA, Williams B, Webb RJ, Denhardt DT, et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood. 2005;106(4):1232–9. doi:10.1182/blood-2004-11-4422.
51. Méndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, MacArthur BD, Lira SA, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466(7308):829–34.
52. Koç ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. JCO. 2000;18(2):307–16.
53. Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells. 2001;19(3):180–92. doi:10.1634/stemcells.19-3-180.
54. Krebsbach PH, Kuznetsov SA, Bianco P, Robey PG. Bone marrow stromal cells: characterization and clinical application. Crit Rev Oral Biol Med. 1999;10(2):165–81.
55. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, et al. Bone histomorphometry: Standardization of nomenclature, symbols, and units: report of the asbmr histomorphometry nomenclature committee. J Bone Miner Res. 1987;2(6):595–610. doi:10.1002/jbmr.5650020617.
56. Raic A, Rödling L, Kalbacher H, Lee-Thedieck C. Biomimetic macroporous PEG hydrogels as 3D scaffolds for the multiplication of human hematopoietic stem and progenitor cells. Biomaterials. 2014;35(3):929–40. doi:10.1016/j.biomaterials.2013.10.038.
57. Nichols JE, Cortiella J, Lee J, Niles JA, Cuddihy M, Wang S, et al. In vitro analog of human bone marrow from 3D scaffolds with biomimetic inverted colloidal crystal geometry. Biomaterials. 2009;30(6):1071–9.
58. Beyer M. New trends and developments in biochemical engineering. Berlin: Springer; 2004.
59. Murphy CM, Haugh MG, O’Brien FJ. The effect of mean pore size on cell attachment, proliferation and migration in collagen–glycosaminoglycan scaffolds for bone tissue engineering. Biomaterials. 2010;31(3):461–6.
60. Weiss L, Geduldig U. Barrier cells: stromal regulation of hematopoiesis and blood cell release in normal and stressed murine bone marrow. Blood. 1991;78(4):975–90.
61. Sharma MB, Limaye LS, Kale VP. Mimicking the functional hematopoietic stem cell niche in vitro: recapitulation of marrow physiology by hydrogel-based three-dimensional cultures of mesenchymal stromal cells. Haematologica. 2011. doi:10.3324/haematol.2011.050500.
62. Azab AK, Runnels JM, Pitsillides C, Moreau A-S, Azab F, Leleu X, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009;113(18):4341–51.
63. Krupnick AS, Shaaban A, Radu A, Flake AW. Bone marrow tissue engineering. Tissue Eng. 2002;8(1):145–55.
64. Chen B, Lin H, Wang J, Zhao Y, Wang B, Zhao W, et al. Homogeneous osteogenesis and bone regeneration by demineralized bone matrix loading with collagen-targeting bone morphogenetic protein-2. Biomaterials. 2007;28(6):1027–35.
65. Wang LD, Wagers AJ. Dynamic niches in the origination and differentiation of haematopoietic stem cells. Nat Rev Mol Cell Biol. 2011;12(10):643–55.
66. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006;25(6):977–88.
67. Winkler IG, Barbier V, Nowlan B, Jacobsen RN, Forristal CE, Patton JT, et al. Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance. Nat Med. 2012;18(11):1651–7.
68. Taichman RS. Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood. 2005;105(7):2631–9.
69. Calvi L, Adams G, Weibrecht K, Weber J, Olson D, Knight M, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425(6960):841–6.
70. Mercier FE, Ragu C, Scadden DT. The bone marrow at the crossroads of blood and immunity. Nat Rev Immunol. 2011;12(1):49–60.
71. Tzeng Y-S, Li H, Kang Y-L, Chen W-C, Cheng W-C, Lai D-M. Loss of Cxcl12/Sdf-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression. Blood. 2011;117(2):429–39.
72. Parmar K, Mauch P, Vergilio J-A, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci. 2007;104(13):5431–6.
73. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10(8):858–64.
74. Majhail NS, Mau LW, Denzen EM, Arneson TJ. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database. Bone Marrow Transplant 2013;48(2):294–300. doi:10.1038/bmt.2012.133.
75. Thomas ED, Buckner CD, Clift RA, Fefer A, Johnson FL, Neiman PE, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med. 1979;301(11):597–9. doi:10.1056/NEJM197909133011109.
76. Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977;49(4):511–33.
77. Sykes M, Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation. Nature. 2005;435(7042):620–7. doi:10.1038/nature03728.
78. Osawa M, Hanada K-I, Hamada H, Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science. 1996;273(5272):242–5.
79. Hinterberger W, Hinterberger-Fischer M, Marmont A. Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases. Bone Marrow Transplant. 2002;30(11):753–9. doi:10.1038/sj.bmt.1703686.
80. Brenner MK, Rill DR, Krance RA, Ihle JN, Moen RC, Mirro J, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993;341(8837):85–6. doi:10.1016/0140-6736(93)92560-G.
81. Radomska HS, Gonzalez DA, Okuno Y, Iwasaki H, Nagy A, Akashi K, et al. Transgenic targeting with regulatory elements of the humanCD34 gene. Blood. 2002;100(13):4410–9. doi:10.1182/blood-2002-02-0355.
82. Rao M, Ahrlund-Richter L, Kaufman DS. Concise review: cord blood banking, transplantation and induced pluripotent stem cell: success and opportunities. Stem Cells. 2012;30(1):55–60. doi:10.1002/stem.770.
83. Takagi M. Cell processing engineering for ex-vivo expansion of hematopoietic cells. J Biosci Bioeng. 2005;99(3):189–96.
84. Panoskaltsis N, Mantalaris A, Wu JD. Engineering a mimicry of bone marrow tissue ex vivo. J Biosci Bioeng. 2005;100(1):28–35.
85. Cook MM, Futrega K, Osiecki M, Kabiri M, Kul B, Rice A, et al. Micromarrows—three-dimensional coculture of hematopoietic stem cells and mesenchymal stromal cells. Tissue Eng Part C Methods. 2012;18(5):319–28.
86. Petite H, Viateau V, Bensaid W, Meunier A, de Pollak C, Bourguignon M, et al. Tissue-engineered bone regeneration. Nat Biotechnol. 2000;18(9):959–63.
87. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356(11):1110–20.
88. Munro N. Hematologic complications of critical illness: anemia, neutropenia, thrombocytopenia, and more. AACN Adv Crit Care. 2009;20(2):145–54.
89. Zhang W, Lee WY, Siegel DS, Tolias P, Zilberberg J. Patient-specific 3D microfluidic tissue model for multiple myeloma. Tissue Eng Part C Methods. 2014;20(8):663–670.
90. Faley SL, Copland M, Wlodkowic D, Kolch W, Seale KT, Wikswo JP, et al. Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells. Lab Chip. 2009;9(18):2659–64.
91. van de Stolpe A, Kauffmann RH. Innovative human-specific investigational approaches to autoimmune disease. RSC Adv. 2015;5(24):18451–63. doi:10.1039/C4RA15794J.
92. Ramadan Q, Gijs MAM. In vitro micro-physiological models for translational immunology. Lab Chip. 2015;15(3):614–36. doi:10.1039/C4LC01271B.
93. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood. 1998;92(8):2908–13.
94. Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood. 1999;94(10):3576–82.
95. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci. 2013;110(9):3507–12.
96. Okuno Y, Iwasaki H, Huettner CS, Radomska HS, Gonzalez DA, Tenen DG, et al. Differential regulation of the human and murine CD34 genes in hematopoietic stem cells. Proc Natl Acad Sci. 2002;99(9):6246–51.
97. Esch MB, Smith AS, Prot J-M, Oleaga C, Hickman JJ, Shuler ML. How multi-organ microdevices can help foster drug development. Adv Drug Deliv Rev. 2014;69:158–69.
98. Sonntag F, Schilling N, Mader K, Gruchow M, Klotzbach U, Lindner G, et al. Design and prototyping of a chip-based multi-micro-organoid culture system for substance testing, predictive to human (substance) exposure. J Biotechnol. 2010;148(1):70–5.